SCHEMBL30795404

SCHEMBL30795404

Clc1c(-c2ccc3c(ccn3-c3cccnc3)c2)ccn2c(CC3CC3)nnc12

nearest known ligand 0.55

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 20/20 0.55
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7860915 1.00 GRM2 (0.55) GRM2KCNH2
SCHEMBL10322993 0.90 GRM2 (0.57) GRM2KCNH2
SCHEMBL7859732 0.88 GRM2 (0.57) GRM2
SCHEMBL10321992 0.87 GRM2 (0.59) GRM2
SCHEMBL10322126 0.86 GRM2 (0.57) GRM2
SCHEMBL7860084 0.85 GRM2 (0.56) GRM2KCNH2
SCHEMBL10321900 0.85 GRM2 (0.54) GRM2KCNH2
SCHEMBL10321108 0.84 GRM2 (0.60) GRM2
SCHEMBL10321710 0.84 GRM2 (0.55) GRM2KCNH2
SCHEMBL10321189 0.83 GRM2 (0.51) GRM2KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4584250-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS Biohaven Therapeutics Ltd. (VG) 2025-07-16 EP disclosed
WO-2024054811-A1 COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS BIOHAVEN THERAPEUTICS LTD. (VG) 2024-03-14 WO disclosed